Indications for TRIZIVIR:
HIV-1 infection.
Adult Dose for TRIZIVIR:
<40kg: not recommended. ≥40kg: 1 tab twice daily.
Children's Dose for TRIZIVIR:
Not recommended.
Pharmacological Class:
Nucleoside analogues (reverse transcriptase inhibitors).
Contraindications:
See literature re: fatal hypersensitivity reactions; signs/symptoms include: fever, rash, nausea, vomiting, diarrhea, abdominal pain, malaise/fatigue, or respiratory symptoms; discontinue as soon as suspected; do not restart, regardless of HLA-B*5701 status. Hepatic impairment.
Warnings/Precautions:
Renal dysfunction (CrCl <50mL/min): not recommended. Evaluate for presence of HLA-B*5701 allele prior to starting therapy or reinitiation; if positive, abacavir is not recommended; discontinue permanently if hypersensitivity cannot be ruled out. Decompensated liver disease or risk factors for liver disease. Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Women, obesity, prolonged nucleoside exposure: increased risk of toxicity. Cardiovascular disease. Diabetes. Smoking. Bone marrow depression. Anemia. Myopathy. Not for treating hepatitis B; monitor patients co-infected with HBV for at least several months after stopping treatment (discontinuing therapy may exacerbate HBV infection). If stopped for reasons other than hypersensitivity, restart only if medical care can be readily accessed; monitor for hypersensitivity. Monitor blood counts. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions:
Avoid zalcitabine, stavudine, doxorubicin, ribavirin, emtricitabine, tenofovir, other forms of abacavir, lamivudine, or zidovudine. Abacavir may antagonize methadone. TMP/SMX, nelfinavir may increase lamivudine levels. Ethanol may increase abacavir levels. Atovaquone, fluconazole, methadone, nelfinavir, probenecid, ritonavir, valproic acid may affect zidovudine levels; monitor. Increased hematologic toxicity with ganciclovir, other bone marrow suppressants or cytotoxic agents. Triple therapy (once daily regimen) with tenofovir or with didanosine + tenofovir: high rate of early viral non-response (see literature). Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin.
Adverse Reactions:
GI upset, anorexia, insomnia, lab abnormalities (anemia, neutropenia, elevated liver enzymes and CPK, mild hyperglycemia, elevated triglycerides), headache, malaise, myopathy, myositis, neuropathy, lactic acidosis, severe hepatomegaly with steatosis, hypersensitivity reactions (may be fatal), nasal symptoms, cough, fever/chills, depression, fat redistribution, rash (may be severe, eg, Stevens-Johnson), dizziness, myalgia, arthralgia, post-treatment exacerbation of hepatitis, immune reconstitution syndrome.
Note:
Register pregnant patients exposed to Trizivir by calling (800) 258-4263. Register patients who have had a hypersensitivity reaction to abacavir by calling (800) 270-0425.
How Supplied:
Tabs—60
